Építés alatt – nem éles oldal
Belépés
Leállítva1/2. fázis

L-DOS47 Plus Doxorubicin in Advanced Pancreatic Cancer

A legfontosabb adatok

Ki végzi
Helix BioPharma Corporation
Hol
Milwaukee, Morristown és Scottsdale (Egyesült Államok)Mind a 3 helyszín megnézése
Azonosító
Állapot
Leállítva
Fázis
1/2. fázis
Résztvevők
28 fő vett részt
Kezdés
2019. dec. 11.
Befejezés
2024. okt. 24.
A vizsgálat típusa
Beavatkozással járó
A vizsgált kezelések
  • L-DOS47
  • Doxorubicin
A regiszteradat frissítve
2025. május 6.
Miért állt le
The primary reason for early termination was budget constraint.

Ki vehet részt

Életkor
18 év felett
Nem
Nők és férfiak
Egészséges önkéntesek
Nem vehetnek részt

A regiszter feltételei, szó szerint

Mind a 25 feltétel megnézéseKevesebb

Ki vehet részt

  • Male or female aged ≥ 18 years old
  • One or more metastatic tumors measurable on computed tomography (CT) scan per RECIST version 1.1 and screening FDG-PET scan with maximum standardized uptake value (SUV max) ≥ 5.5 for at least one lesion consistent with pancreatic cancer
  • Karnofsky performance status ≥ 70%
  • Life expectancy of at least 3 months
  • Able to understand the information provided to them and to give written institutional review board (IRB)-approved informed consent prior to any study activities being conducted
  • A negative pregnancy test (if of child bearing potential)
  • Acceptable liver function:; Bilirubin ≤ 1.5 times upper limit of normal; Aspartate aminotransferase (AST), alanine aminotransferase (ALT) and Alkaline phosphatase (ALP) ≤ 2.5 times upper limit of normal (ULN; if liver metastases are present, then ≤ 5 x ULN is allowed)
  • Acceptable renal function as defined by creatinine ≤1.5x institutional upper limits of normal, or calculated creatinine clearance ≥ 60 mL/min/1.73 m2 for patients with creatinine levels above institutional normal
  • Acceptable hematologic status:; Granulocyte ≥ 1500 cells/mm3; Platelet count ≥ 100,000 (plt/mm3); Hemoglobin ≥ 9g/dL
  • Urinalysis:; No clinically significant abnormalities
  • Acceptable coagulation status; Prothrombin time within 1.5x of normal limits; Partial thromboplastin time (PTT) within 1.5x of normal limits
  • For men and women of child-bearing potential, the use of effective contraceptive methods during the study
  • Normal ejection fraction on ECHO or MUGA

Ki nem vehet részt

  • Pregnant or nursing women. NOTE: Women of childbearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; or abstinence) prior to study entry and for the duration of study participation. Should a woman become pregnant while participating in this study, she should inform her treating physician immediately
  • Treatment with radiation therapy, surgery, chemotherapy, or investigational therapy within 3 weeks prior to study entry
  • Major surgery within 4 weeks prior to study entry
  • Patients who are currently receiving any other investigational agent
  • New York Heart Association Class III or IV, cardiac disease, myocardial infarction within the past 6 months, unstable arrhythmia, or evidence of ischemia on ECG
  • Active, uncontrolled bacterial, viral, or fungal infections requiring systematic therapy
  • Known infection with HIV, hepatitis B, or hepatitis C
  • Serious nonmalignant disease (eg hydro nephrosis, liver failure, or other conditions) that could compromise protocol objectives in the opinion of the investigator and/or the sponsor
  • Abnormal ejection fraction on ECHO or MUGA
  • Patients with marked screening prolongation of QT/QTc interval (e.g. repeated demonstration of a QTc interval > 480 milliseconds (CTCAE grade 1) using Fredericia's QT correction formula
  • Unwillingness or inability to comply with procedures required in this protocol
  • Patients with any evidence of uncontrolled brain metastases or carcinomatosis meningitis

Helyszínek itt: Egyesült Államok

  • Froedtert Hospital and the Medical College of WisconsinMilwaukee, Egyesült Államok
  • Atlantic Health System / Morristown Medical CenterMorristown, Egyesült Államok
  • Scottsdale Healthcare Hospitals DBA HonorHealthScottsdale, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.

A vizsgálat csoportja

  • L-DOS47 + doxorubicinA vizsgált kezelés

    Patients will be recruited into escalating dosing cohorts of 3, 6 and 9 µg/kg of L-DOS47, with a minimum of 3 and a maximum of 6 patients per cohort. A fixed dose of intravenous doxorubicin \[20 mg/m2/week\] will be administered in combination with L-DOS47 across all cohorts.

    Kezelés: L-DOS47 és Doxorubicin

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 Plus Doxorubicin for the Treatment of Patients With Previously Treated Advanced Pancreatic Cancer
A regiszteradat frissítve
2025. május 6.